Combining a fasting mimicking diet with chemotherapy for leukemia patients
The Effect of Fasting Mimicking Diet With Chemotherapy on the Number of Blasts and Platelets and Quality of Life in Patients With Acute Lymphoid Leukemia and Acute Myeloid Leukemia
This study is testing if combining a fasting mimicking diet with chemotherapy can improve treatment results and quality of life for patients with acute lymphoid and acute myeloid leukemia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Nutrition and Food Technology Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Tehran, Middle East and 1 other locations) |
| Trial ID | NCT06353698 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of a fasting mimicking diet in conjunction with chemotherapy on patients diagnosed with acute lymphoid leukemia and acute myeloid leukemia. The study aims to assess changes in the number of leukemia blasts, platelet counts, and overall quality of life for participants. By integrating dietary interventions with standard chemotherapy, the trial seeks to explore potential synergistic effects that could enhance treatment outcomes. Participants will be monitored throughout the intervention to evaluate both clinical and quality of life metrics.
Who should consider this trial
Good fit: Ideal candidates are individuals recently diagnosed with acute leukemia who are set to begin chemotherapy and have a BMI greater than 18.5.
Not a fit: Patients with diabetes, metastases to other organs, or those unwilling to comply with the study requirements may not benefit from this trial.
Why it matters
Potential benefit: If successful, this approach could improve treatment efficacy and quality of life for patients undergoing chemotherapy for leukemia.
How similar studies have performed: While the combination of dietary interventions with chemotherapy is an emerging area of interest, this specific approach has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * People who have recently been diagnosed with acute leukemia pathology and have been prescribed chemotherapy * Willingness to cooperate * BMI \>18.5 Exclusion Criteria: * diabetes * metastases to other organ * Unwillingness to continue the study by patients
Where this trial is running
Tehran, Middle East and 1 other locations
- Azita Hekmatdoost — Tehran, Middle East, Iran, Islamic Republic of (Recruiting)
- Ehsan Hejazi — Tehran, Iran, Islamic Republic of (Recruiting)
Study contacts
- Principal investigator: Ehsan Hejazi, PhD — Beheshti University of Medical Sciences
- Study coordinator: Ehsan Hejazi, PhD
- Email: ehsanhejazi@gmail.com
- Phone: 00989121530775
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.